Bart Mulder

Cardiologist

Bart Mulder is a cardiologist with a focus on invasive treatment of cardiac arrhythmias. He did his PhD at the University of Groningen on the treatment of atrial fibrillation in patients with heart failure. His other topics of interest are invasive treatment of atrial fibrillation and novel therapies for cardiac arrhythmias. He is involved in the atrial fibrillation focused research and clinical ablation studies currently ongoing in the UMCG. His research is supported by the European Society of Cardiology council for stroke research grant.

Contact details

b.a.mulder@umcg.nl +31 50 361 61 61

We are currently investigating tissue characteristics of patients with atrial fibrillation in the RACE V-trial, further exploring risk factors that may help to identify which patients fail after hybrid or catheter ablation treatment for atrial fibrillation, and are exploring the contribution of integration of cardiac imaging with electroanatomical mapping to guide catheter ablation.

My publications

Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.

The objective of this study was to assess the association of digoxin with cardiovascular (CV) morbidity and mortality in patients with permanent atrial fibrillation enrolled in the Dutch Rate Control Efficacy in Permanent AF: A Comparison Between Lenient Versus Strict Rate Control II trial as well as to assess the role of digoxin to achieve heart rate targets. The use of digoxin was not associated with increased morbidity and mortality.

view on Heart Rhythm Journal

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

Heart failure with preserved ejection fraction and AF are very common diseases that also often occur in combination, further aggravating each other. Senile amyloidosis, either due to TTR (ATTRwt) or ANP (IAA) appears to play an important role in both diseases and in their interaction. In terms of diagnostics, bone scintigraphy has become available and affords an easy and reliable way to establish the presence of cardiac ATTRwt. Moreover, pharmacological options are now available or under development to treat ATTRwt and possibly also IAA, thereby potentially stopping, or even reversing, the downhill course of some patients with HFpEF and AF.

view on Oxford Academic

Pulmonary vein anatomy addressed by computed tomography and relation to success of second-generation cryoballoon ablation in paroxysmal atrial fibrillation.

The aim of this study was to assess PV morphology and variants including carina width, shared carina or PV ovality index and whether this is of influence on AF recurrence after PVI with the second generation 28 mm cryoballoon in a homogenous population of patients with paroxysmal AF. No specific characteristics of PV dimensions nor morphology were associated with AF recurrence after cryoballoon ablation in patients with paroxysmal AF.

view on Wiley Online Library